Reduction of repolarization reserve increases the risk of arrhythmia. We hypothesized that inhibition of K ϩ current (IK) to decrease repolarization reserve would unmask the proarrhythmic role of endogenous, physiological late Na ϩ current (late INa). Monophasic action potentials (MAP) and 12-lead electrocardiogram were recorded from female rabbit isolated hearts. To block I K and reduce repolarization reserve, E-4031, 4-aminopyridine, and BaCl 2 were used; to block endogenous late INa, tetrodotoxin (TTX) and ranolazine were used. E-4031 (1-60 nM) concentrationdependently prolonged MAP duration (MAPD 90) and increased duration of the T wave from T peak to Tend (Tpeak-Tend), transmural dispersion of repolarization (TDR), and beat-to-beat variability (BVR) of MAPD 90. E-4031 caused spontaneous and pause-triggered polymorphic ventricular tachycardia [torsade de pointes (TdP)]. In the presence of 60 nM E-4031, TTX (0.6 -3 M) and ranolazine (5-10 M) shortened MAPD 90, decreased TDR, BVR, and Tpeak-Tend (n ϭ 9 -20, P Ͻ 0.01), and abolished episodes of TdP. In hearts treated with BaCl 2 or 4-aminopyridine plus E-4031, TTX (0.6 -3 M) shortened MAPD 90 and decreased T peak-Tend. Ranolazine could not reverse the effect of E-4031 to inhibit human ether-a-go-go-related gene (HERG) K ϩ current; thus, the reversal by ranolazine of effects of E-4031 was likely due to inhibition of late I Na and not to antagonism of the HERG-blocking action of E-4031. We conclude that endogenous, physiological late I Na contributes to arrhythmogenesis in hearts with reduced repolarization reserve. Inhibition of this current partially reverses MAPD prolongation and abolishes arrhythmic activity caused by I K inhibitors. late sodium current; repolarization reserve; ventricular tachycardia; monophasic action potential; ion currents THE PLATEAU AND DURATION OF the cardiac action potential (AP) depends on a delicate balance of multiple ion channel currents, including inward (peak and late Na ϩ and Ca 2ϩ ) and outward [transient outward (I to ), inward-rectifier (I K1 ), and delayedrectifier (I K ) K ϩ ] currents. A decrease in outward or an increase in inward current prolong the duration of the AP (and its electrocardiographic surrogate, the QT interval) and are associated with an increased incidence of polymorphic ventricular tachycardia (torsade de pointes, TdP). (21) The concept of repolarization reserve suggests that there is normally a reserve of repolarizing current to protect against excessive QT interval prolongation and ventricular arrhythmia. (23) Reduction of repolarization reserve has been associated with an increased risk of arrhythmogenesis in patients with inherited long QT syndromes and/or structural heart disease, and in patients treated with QT-prolonging drugs (21-23, 31). Factors that either increase inward currents or decrease outward currents during repolarization of the cardiac AP are associated with reduced repolarization reserve and are arrhythmogenic.
To block I K and reduce repolarization reserve, E-4031, 4-aminopyridine, and BaCl 2 were used; to block endogenous late INa, tetrodotoxin (TTX) and ranolazine were used. E-4031 (1-60 nM) concentrationdependently prolonged MAP duration (MAPD 90) and increased duration of the T wave from T peak to Tend (Tpeak-Tend), transmural dispersion of repolarization (TDR), and beat-to-beat variability (BVR) of MAPD 90. E-4031 caused spontaneous and pause-triggered polymorphic ventricular tachycardia [torsade de pointes (TdP)]. In the presence of 60 nM E-4031, TTX (0.6 -3 M) and ranolazine (5-10 M) shortened MAPD 90, decreased TDR, BVR, and Tpeak-Tend (n ϭ 9 -20, P Ͻ 0.01), and abolished episodes of TdP. In hearts treated with BaCl 2 or 4-aminopyridine plus E-4031, TTX (0.6 -3 M) shortened MAPD 90 and decreased T peak-Tend. Ranolazine could not reverse the effect of E-4031 to inhibit human ether-a-go-go-related gene (HERG) K ϩ current; thus, the reversal by ranolazine of effects of E-4031 was likely due to inhibition of late I Na and not to antagonism of the HERG-blocking action of E-4031. We conclude that endogenous, physiological late I Na contributes to arrhythmogenesis in hearts with reduced repolarization reserve. Inhibition of this current partially reverses MAPD prolongation and abolishes arrhythmic activity caused by I K inhibitors. late sodium current; repolarization reserve; ventricular tachycardia; monophasic action potential; ion currents THE PLATEAU AND DURATION OF the cardiac action potential (AP) depends on a delicate balance of multiple ion channel currents, including inward (peak and late Na ϩ and Ca 2ϩ ) and outward [transient outward (I to ), inward-rectifier (I K1 ), and delayedrectifier (I K ) K ϩ ] currents. A decrease in outward or an increase in inward current prolong the duration of the AP (and its electrocardiographic surrogate, the QT interval) and are associated with an increased incidence of polymorphic ventricular tachycardia (torsade de pointes, TdP). (21) The concept of repolarization reserve suggests that there is normally a reserve of repolarizing current to protect against excessive QT interval prolongation and ventricular arrhythmia. (23) Reduction of repolarization reserve has been associated with an increased risk of arrhythmogenesis in patients with inherited long QT syndromes and/or structural heart disease, and in patients treated with QT-prolonging drugs (21) (22) (23) 31) . Factors that either increase inward currents or decrease outward currents during repolarization of the cardiac AP are associated with reduced repolarization reserve and are arrhythmogenic.
A rapid, inward Na ϩ current (I Na ) flowing through voltagegated Na ϩ channels accounts for the upstroke of the cardiac AP. This I Na normally inactivates rapidly and is thus thought to exert minimal influence on AP duration (APD), except perhaps in Purkinje fibers (5, 10) . However, late reopenings of Na ϩ channels during the plateau of the AP lead to a small 30-to 60-pA physiological, persistent late I Na in ventricular myocytes (7, 13, 38) . During the plateau of the AP, when membrane resistance is high and the total membrane current is small, this endogenous late I Na may have a significant effect to prolong the APD, especially when K ϩ current (I K ) is reduced. The significance of this effect is not clear, but basic and clinical research results suggest that simultaneous enhancement of late I Na [e.g., caused by sea anemone toxin II (ATX-II)] and reduction of I K is markedly proarrhythmic (6, 15, 17, 35, 36) . We hypothesized that even the normal endogenous (nonenhanced) physiological late I Na may be proarrhythmic when I K is inhibited and net repolarizing current, and therefore repolarization reserve, is decreased. Therefore, to "unmask" the potential proarrhythmic role of endogenous late I Na when I K is reduced, we exposed rabbit hearts to proarrhythmic concentrations of inhibitors of the rapidly activating I Kr , I to , and I K1 currents and then determined the effects of late I Na inhibitors on ventricular repolarization and arrhythmic activity. Tetrodotoxin (TTX) and ranolazine were used to inhibit late I Na . TTX is a selective inhibitor of voltage-gated Na ϩ channels and inhibits both peak and late I Na . Ranolazine is a selective inhibitor of late I Na relative to peak I Na , but the selectivity of ranolazine for inhibition of late I Na relative to inhibition of human ether-a-go-go-related gene (HERG) K ϩ current (I HERG ) is only twofold.(4) The mechanism explaining the effect of ranolazine to antagonize arrhythmias caused by I Kr inhibition (27, 32, 36, 37) still needs clarification. We therefore determined the nature of the functional antagonism of effects of E-4031 by ranolazine that were observed in hearts in this study, by comparing the effects of ranolazine and E-4031 on I HERG in human embryonic kidney (HEK 293) cells expressing either wild-type HERG channels or HERG channels with drugbinding site mutations.
MATERIALS AND METHODS

Female Rabbit Isolated Heart Model
The use of animals in this investigation conformed to the "Guide for the Care and Use of Laboratory Animals" published by the United States National Institutes of Health (NIH publication no. 85-23, revised 1996), and animal use was approved by the Institutional Animal Care and Use Committee of CV Therapeutics (Palo Alto, CA). New Zealand White female rabbits weighing 2.5-3.5 kg were used in this study. Female rabbit hearts were isolated, perfused by the method of Langendorff, and instrumented for recording of electrical activity as previously described by Wu et al. (35, 36) . Hearts were submerged in a temperature-controlled bath at 37°C during experiments. Monophasic action potential (MAP) and pseudo 12-lead electrocardiogram (ECG) records were obtained, and transmural dispersion of repolarization (TDR) and beat-to-beat variability of repolarization (BVR) were determined as described by Wu et al. (34, 35) . Drug effects on ECG parameters such as the duration of the T wave from T peak to Tend (Tpeak-Tend) and the QT and QRS intervals were determined by superimposing 12-lead ECG signals recorded from the heart during steadystate control and treatment periods.
Determination of Concentration-Response Relationships for Effects of E-4031, TTX, and Ranolazine on Ventricular Arrhythmias and Electrophysiological Parameters
Hearts were exposed to increasing concentrations of E-4031 (1-60 nM), TTX (0.1-10 M), and ranolazine (1-100 M) in a cumulative manner, allowing 7-15 min between increases in drug concentration to facilitate the recording of a steady-state maximal effect.
Determination of the Anti-arrhythmic Effects of TTX and Ranolazine on Ventricular Arrhythmias in the Presence of E-4031
Hearts were perfused with E-4031 (60 nM) for 20 min to induce arrhythmias and then exposed to either TTX (0.3, 0.6, 1, and 3 M) or ranolazine (5, 10, and 30 M) in the continued presence of 60 nM E-4031. Electrophysiological parameters were monitored continuously for the occurrence of ectopic ventricular beats (EVBs), early afterdepolarizations (EADs), and ventricular tachycardias (VT). Postdrug exposure values of MAP duration (MAPD) were obtained when drug washout was completed. An EVB was defined as a spontaneous beat occurring earlier than the next paced beat. VT was defined as a sequence of three or more consecutive EVBs at a rate exceeding the pacing rate of 1 Hz. A TdP was defined as a VT wherein the morphology of the QRS complexes in a 12-channel ECG record were continuously changing. An EAD was defined as a positive depolarization during phase 2 and/or 3 of an MAP signal. Repeated 3-s pauses in ventricular electrical stimulation were used to induce pause-triggered EVBs, EADs, and VT in the absence and presence of drugs. Pause-triggered EADs and ventricular arrhythmias were defined as EAD, EVBs, or VT that occurred within the first three beats after ventricular pacing was resumed.
Determination of the Effects of E-4031, TTX, and Ranolazine on Peak and Late I Na and IHERG in HEK 293 Cells Expressing Either SCN5A or HERG K
ϩ Channels
Heterologous expression of SCN5A Na ϩ and HERG K ϩ channels. HEK 293 cells stably expressing the human heart Na ϩ channel (hH1a; Nav1.5) clone of SCN5A gene (␣-subunit) or the HERG K ϩ channels (wild-type) were maintained as described previously (35) . With the use of site-directed mutagenesis, two HERG drug-binding mutations, Y652A and F656A, were generated and were stably expressed in HEK 293 cells. CA). pCLAMP 9.0 software (Axon Instruments) was used to generate voltage-clamp protocols and acquire data. Patch pipettes were pulled from borosilicate glass (World Precision Instruments, Sarasota, FL) using a DMZ Universal puller (Dagan, Minneapolis, MN). All patch-clamp experiments were performed at a room temperature of 19 Ϯ 1°C.
Recordings of peak and late I Na and IHERG with whole cell voltage-clamp technique. Whole cell
For recording of I Na, cells were superfused with Tyrode solution containing (in mM): 140 NaCl, 4.0 KCl, 1.8 CaCl2, 0.75 MgCl2, and 5 HEPES (pH adjusted to 7.4 with NaOH). Pipette resistance was 1-2 M⍀ when filled with a pipette (internal) solution containing (in mM): 20 CsCl, 120 CsF, 2 EGTA, and 5 HEPES (pH adjusted to 7.4 with CsOH). Membrane potentials were not corrected for junction potentials that arise between the pipette and bath solutions. For recording of I HERG, cells were superfused with Tyrode solution containing (in mM): 137 NaCl, 4.0 KCl, 1.8 CaCl 2, 1 MgCl2, 10 glucose, and 10 HEPES; pH was adjusted to 7.4 with NaOH. Pipettes were filled with a solution containing (in mM): 130 KCl, 1 MgCl 2, 5 MgATP, and 5 EGTA; pH was adjusted to 7.2 with KOH. In all recordings, 75-80% of the series resistance compensation was achieved, yielding a maximum voltage error of ϳ5 mV. To measure the tonic block (i.e., block of current that is independent of the frequency of channel activity) by ranolazine or TTX of peak I Na, 24-ms depolarizing steps to Ϫ20 mV from a holding potential of Ϫ140 mV were applied to cells at a rate of 0.1 Hz. To measure the effect of ranolazine or TTX on late I Na, the normally small late I Na (Ϫ68.4 Ϯ 14.7 pA, n ϭ 8 cells) was augmented by exposure of cells to 3 nM ATX-II, and the effect of ranolazine or TTX to reduce the augmented late INa was determined in the presence of 3 nM ATX-II. Late INa was defined as the magnitude of I Na between 650 and 700 ms after application (at a rate of 0.1 Hz) of a 700-ms depolarizing step to Ϫ20 mV from a holding potential of Ϫ140 mV. IHERG was activated with a step to 20 mV, and tail current was recorded after a subsequent step to Ϫ50 mV. The voltage protocol was repeated at 15-s intervals.
To validate the use of TTX and ranolazine as selective inhibitors of INa, specifically late INa, the concentration-response relationships for these agents to inhibit peak and late INa and IHERG were determined in preliminary experiments. HEK 293 cells expressing either human NaV1.5 (SCN5A) Na ϩ channels or HERG K ϩ channels were used for these experiments. TTX concentration dependently inhibited peak and late INa (augmented by ATX-II) but not IHERG (Fig. 1, A and B) . The values for drug concentration that causes 50% block (IC50) and the Hill number (nH; in parentheses) for the inhibitions by TTX of peak (0.71 Ϯ 0.12), and 14.44 Ϯ 3.58 M (1.01 Ϯ 0.11), respectively (n ϭ 4 -8 cells each; Fig. 1F ).
Statistical Analyses
All data are reported as means Ϯ SE. The concentration-response relationships were analyzed using Prism version 5 (GraphPad Software, San Diego, CA). When control and treatment values were obtained from the same hearts, the significance of differences of measures before and after interventions was determined by repeatedmeasure one-way ANOVA followed by the Student-Newman-Keul's test. A paired or unpaired Student's t-test was used to determine the statistical difference between values of two means obtained from the same or different experiments, respectively. For categorical data, a Chi square test was used.
Ion current data were analyzed using Clampfit and Microcal Origin (MicroCal, Northampton, MA) software. Values of peak and late I Na and peak tail IHERG were normalized to the respective control values and are plotted as relative currents. Concentrationresponse relations were fitted using the Hill equation,
Materials
E-4031, 4-aminopyridine (4-AP), and BaCl2 were purchased from Sigma Chemical (St Louis, MO). TTX and ATX-II were purchased from Alomone Labs (Jerusalem, Israel). Ranolazine was synthesized by the Department of Bio-Organic Chemistry at CV Therapeutics (Palo Alto, CA). HEK 293 cells stably expressing the human heart Na ϩ channel (hH1a; Nav1.5) clone of SCN5A gene (␣-subunit alone) or stably expressing HERG K ϩ channels that were originally developed in the laboratory of Dr. Craig T. January were purchased from Cytomyx (Cambridge, UK) and from the University of Wisconsin (Madison, WI), respectively.
RESULTS
E-4031 and Ranolazine, but not TTX, Prolonged MAPD 90 in Female Rabbit Isolated Hearts
E-4031 (1-60 nM) caused concentration-dependent prolongations of epi-and endocardial MAPD 90 by up to 41 Ϯ 3 and 64 Ϯ 6%, respectively (n ϭ 40, P Ͻ 0.001; Figs. 2,  A and B, 3, and 4, A and B) , and increased TDR from 20 Ϯ 4 to 74 Ϯ 10 ms (n ϭ 39, P Ͻ 0.001; Fig. 4C ), BVR from 0.24 Ϯ 0.02 to 0.75 Ϯ 0.05 ms (n ϭ 18, P Ͻ 0.01; Fig. 4D ), T peak -T end from 34 Ϯ 1 to 102 Ϯ 6 ms (n ϭ 38, P Ͻ 0.01; Fig. 4E ) and QT interval from 249 Ϯ 4 to 429 Ϯ 15 ms (n ϭ 21, P Ͻ 0.01; data not shown). TTX (0.1-10 M) alone did not cause significant changes in either epi-or endo-MAPD 90 (Fig. 2, C and D Fig. 2, E and F) and QT interval from 249 Ϯ 13 to 286 Ϯ 13 ms (n ϭ 5, P Ͻ 0.01, not shown) without increasing the TDR (21 Ϯ 4 ms in control and 22 Ϯ 5 ms with 100 M ranolazine, n ϭ 16, P Ͼ 0.05).
Effects of TTX and Ranolazine on MAPD Prolongation and Arrhythmic Activities of E-4031
In the presence of 60 nM E-4031, both TTX (0. (Fig. 4, C-E) , and the QT interval (n ϭ 9 -20, P Ͻ 0.01 and 0.001; data not shown) in the presence of 60 nM E-4031, in a concentration-dependent manner. However, although TdP was not observed in hearts exposed to 60 nM E-4031 in the presence of either 3 M TTX or 30 M ranolazine, neither TTX nor ranolazine was able to fully reverse the effects of 60 nM E-4031 on other measures of proarrhythmic activity (Fig.  4, A-E) .
Spontaneous or 3-s pause-triggered EADs, frequent EVBs, and episodes of TdP were induced in 20 out of 25 (80%) hearts treated with 60 nM E-4031 (Figs. 4F and 5, B and E). Both TTX (0.6 -3 M) and ranolazine (5-30 M) concentration dependently abolished the spontaneous and 3-s pause-triggered episodes of TdP caused by 60 nM E-4031 (Figs. 4F and 5, C and F) . The effects of TTX (data not shown) and ranolazine were reversible, and their washout in the presence of E-4031 resulted in a reappearance of TdP (Fig. 5G) .
Exposure of hearts to TTX at concentrations of 3, 10, and 30 M (but not at 0.3 or 0.6 M) resulted in increases of the QRS interval by 5 Ϯ 1, 29 Ϯ 6, and 67 Ϯ 10 ms (n ϭ 12, P Ͻ 0.01; data not shown), respectively. Hence, the effects of TTX to shorten MAPD 90 in presence of E-4031 at concentrations Յ1 M were unlikely to be due to the inhibition of peak I Na .
Neither E-4031 nor ranolazine increased the QRS interval at concentrations used in these experiments.
Effects of the Late I Na Inhibitor TTX to Attenuate MAPD Prolongation and Arrhythmic Activity Caused by 4-AP Plus E-4031, or by BaCl 2
To further demonstrate that inhibition of physiological late I Na reduces the proarrhythmic effects of I K inhibitors, hearts were treated with the K ϩ channel inhibitors 4-AP, E-4031, or BaCl 2 in the absence and presence of the late I Na inhibitor, TTX. 4-AP is a selective I to inhibitor at low concentrations (9, 11). Both 4-AP (100 M) and a low concentration of E-4031 Fig. 6A ), respectively, without causing TdP. The combination of 4-AP (100 M) and E-4031 (30 nM) caused a much greater increase in MAPD to 310 Ϯ 7 ms, and caused TdP in all hearts studied (n ϭ 14). In the presence of 4-AP (100 M) and E-4031 (30 nM), TTX shortened the MAPD and decreased T peak -T end in a concentration-dependent manner (P Ͻ 0.01, Fig. 6A ). Although frequent episodes of TdP were observed in the presence of 4-AP (100 M) plus E-4031 (30 nM), no episodes of TdP were observed in the presence of these agents when 0.3-3 M TTX was also present (Fig. 6A) .
BaCl 2 at concentrations of 10 -50 M selectively blocks I K1 (8, 33) . BaCl 2 (30 M) significantly prolonged epi-MAPD and T peak -T end from 190 Ϯ 4 and 35 Ϯ 2 to 277 Ϯ 6 and 79 Ϯ 5 ms (n ϭ 8, P Ͻ 0.01, Fig. 6B ), respectively, but did not cause TdP. In the continued presence of 30 M BaCl 2 , TTX (0.6 -3 M) in a concentration-dependent manner shortened MAPD and decreased T peak -T end (P Ͻ 0.05-0.01, Fig. 6B ).
Ranolazine Shared a Binding Domain with E-4031 in HERG Channels
E-4031 and ranolazine inhibit I HERG with high and low potencies, respectively (4, 20, 30) , and prolong the duration of the AP (Fig. 2) . The functional antagonism by ranolazine of the effects of E-4031 to increase MAPD (Figs. 3 and 4) and markers of proarrhythmic activity (Fig. 4, C and D) , and to cause TdP (Fig. 4F) , could be the result of the reduction by ranolazine of late I Na , but it could also be due to displacement by ranolazine of E-4031 from the HERG channel. To address the latter, antagonism by each drug of the effect of the other to inhibit I HERG was investigated. In preparations of HEK 293 cells stably expressing HERG K ϩ channels, superfusion of either 300 M ranolazine ( Fig. 7A and inset) or 0.3 M E-4031 ( Fig. 7B and inset) caused a rapid and nearly complete reduction in I HERG amplitude. The recovery of I HERG was rapid and complete after washout of ranolazine (Fig. 7A) . In contrast, the recovery of I HERG after washout of E-4031 was negligible (Fig.  7B) . The amplitude of peak tail I HERG after 9 min washout of E-4031 was only 15.6 Ϯ 5.7% of the predrug amplitude ( Fig.  7B and inset) . To determine if ranolazine and E-4031 shared a similar binding domain to cause inhibition of I HERG , cells were c) , and after washout (d). Scale in inset: horizontal and vertical bars represent 2 s and 250 pA, respectively. C and D: peak tail IHERG amplitude during exposures to Ran alone and then Ran ϩ E-4031 or to E-4031 alone and then E-4031 ϩ Ran, respectively, followed by washout of both drugs. exposed to 300 M ranolazine, and then to E-4031 (0.3 M) in the continued presence of ranolazine, after which both drugs were washed out (Fig. 7C) . The recovery of I HERG was nearly complete after washout of both drugs, since the peak tail I HERG amplitude recovered to 91.9 Ϯ 2.1% of control (n ϭ 3 cells, P Ͻ 0.05 compared with E-4031 alone; Fig. 7C ). When the order of exposure to ranolazine and E-4031 was reversed and cells were exposed first to 0.3 M E-4031, and then to 300 M ranolazine in the continued presence of E-4031, there was minimal recovery in peak tail I HERG amplitude after washout of both drugs, to only 10.7 Ϯ 2.3% (n ϭ 3 cells) of control (Fig.  7D) . The result that saturating the HERG drug-binding site with ranolazine prevented E-4031 from having an effect suggests that binding of ranolazine and E-4031 to HERG was not concurrent, but that the binding of one prevented the binding of the other. However, although ranolazine acutely reversed MAPD in the presence of E-4031 (Figs. 3B, 4B , and 5F), it did not acutely reverse the inhibitory effect of E-4031 on I HERG , suggesting that it did not displace E-4031 binding.
To further elucidate the binding sites for ranolazine and E-4031 in the HERG channel, the effects of both compounds to inhibit I HERG in cells with mutant HERG K ϩ channels (Y652 or F656A) (17) were studied. The concentration-response relationships for both ranolazine and E-4031 to inhibit I HERG in cells with mutant HERG channels were shifted to the right by Ͼ10-fold (Fig. 8 ). Ranolazine at concentrations as high as 300 M caused only ϳ33% (n ϭ 4 cells) and 26% (n ϭ 4 cells) block of I HERG in cells expressing Y652A and F656A mutant channels, respectively, whereas wild-type HERG channels were nearly completely blocked by 100 M ranolazine (Fig.  8A) . Similarly, the IC 50 values of 0.36 and 0.56 M for E-4031 to block I HERG in cells expressing mutant channels Y652A (n ϭ 4 cells, each) and F656A (n ϭ 4 cells, each) were significantly greater than the IC 50 value for E-4031 to block I HERG in cells expressing wild-type channels (15.8 nM; Fig.  8B ). These data suggest the possibility that ranolazine and E-4031 compete for a common site in the HERG channel pore. However, ranolazine could not displace the tightly bound E-4031 during the brief duration of experiments (e.g., 10 min in Fig. 7 ). Thus the data are consistent with the hypothesis that ranolazine antagonized the effect of E-4031 by inhibiting late I Na .
DISCUSSION
The main finding of this study is that endogenous (physiological) late I Na , although small in amplitude (8 -10) , modulated ventricular repolarization, APD, and arrhythmogenesis when repolarization reserve was decreased by treatments of rabbit hearts with 4-AP, E-4031, or BaCl 2 to decrease I to , I Kr , and I K1 , respectively. Either TTX at low (Յ1 M) or ranolazine at therapeutic (2-10 M) concentrations significantly decreased MAPD 90 , TDR, BVR, T peak -T end , and QT interval, and abolished the EADs, EVBs, and TdP caused by the I Kr inhibitor E-4031. Ranolazine or TTX partially reversed the prolongations of MAPD and arrhythmogenesis caused by the high-affinity and potent I Kr inhibitor E-4031 (Figs. 3-5) . TTX shortened the MAPD caused by either a combination of the I to inhibitor 4-AP with E-4031, or the I K1 inhibitor BaCl 2 (30 M) (Fig. 6) . The results suggest that endogenous late I Na contributes to prolongation of the APD and is arrhythmogenic in hearts with decreased repolarization reserve, and that inhibition of this small current reduces arrhythmogenic activity. This finding may explain observations that Na ϩ channel inhibitors are able to reverse the proarrhythmic, electrophysiological effects of various I K inhibitors on the heart (1, 19) .
Ranolazine is a selective inhibitor of late vs. peak I Na (4). In HEK 293 cells, ranolazine inhibited late I Na and I Kr with potencies of 6.9 Ϯ 1.6 and 14.4 Ϯ 3.4 M (Fig. 1F) ; these values are similar to those reported in a study of canine ventricular myocytes (4) . Thus the anti-arrhythmic effect of ranolazine in experiments with E-4031 in this study could potentially be due either to reduction of late I Na or to displacement of the I Kr inhibitor E-4031 from its binding site in the HERG channel pore. Electrophysiological studies of HERG channels expressed in HEK 293 cells indicated that ranolazine and E-4031 shared the same binding domain to inhibit I HERG but that ranolazine could not competitively displace E-4031 (Fig. 7) . This finding suggests that the effect of ranolazine to reverse actions of E-4031 (Figs. 3-5) is the result of inhibition of late I Na by ranolazine, rather than displacement of E-4031 from the HERG channel protein.
TTX inhibited Na V 1.5 late I Na at lower concentrations than it inhibited Na V 1.5 peak I Na in this study, with potencies of 0.5 Ϯ 0.1 and 6.0 Ϯ 0.4 M, respectively (Fig. 1C) . Thus, at concentrations of 0.6 -1 M, TTX is a relatively selective inhibitor of late I Na . Therefore, the effects of ranolazine as well as those of TTX (which is not an inhibitor of HERG) to reduce MAPD and arrhythmic activity were due to their reduction of late I Na . The results indicate that endogenous late I Na in rabbit hearts with reduced repolarization reserve is an important regulator of both APD and ventricular arrhythmic activity.
Potential causes of reduced repolarization reserve include gene mutations or polymorphisms that enhance late I Na or Ca 2ϩ current, mutations in K ϩ channels that result in decreased outward I K , drugs that affect ion channels (e.g., inhibitors of I Kr ), electrolyte abnormalities (hypokalemia and hypomagnesia), and structural heart diseases (heart failure and myocardial ischemia) (14, 16, 21, 22, 28, 29) . A reduction of net outward current during phase 3 of the ventricular AP (i.e., reduced repolarization reserve) is potentially proarrhythmic, especially when associated with AP triangulation, reverse rate dependency, and increased dispersion of repolarization (3, 12) . In a study of cardiomycytes isolated from hearts of dogs with heart failure and arrhythmias, Maltsev et al. (16) reported that EADs ceased and both APD and BVR returned to normal when late I Na was partially inhibited by TTX or saxitoxin, and when outward current was injected (50 pA ϫ 200 ms) during the AP plateau. Injecting current opposite in direction to late I Na (which is an inward current) did not alter the contribution of peak I Na to the AP upstroke and to Na ϩ entry, but yet confirmed the effect of a relatively small current to alter repolarization, APD, and arrhythmic activity (16) . Because AP prolongation alone may not be a good predictor of proarrhythmic risk (5), the specific current(s) affected and the nature of the changes precipitated as a result may modify or determine risk. For example, an increase of late I Na is reported to lead to EAD and delayed afterdepolarization (DAD) formation and dispersion of repolarization (34) , all of which are proarrhythmic. Potential reasons for the marked proarrhythmic effect of late I Na are that late I Na peaks during phase 3 of the AP when repolarization begins, due to an increase of the driving force for Na ϩ entry (34) , and Na ϩ entry leads to increased Na ϩ /Ca 2ϩ exchange and Ca 2ϩ entry, which may lead to Ca 2ϩ loading of the sarcoplasmic reticulum, and DADs. In addition, a reduction of repolarization reserve by one mechanism (e.g., reduction of I Kr ) can sensitize the myocardium to the proarrhythmic effects of drugs or conditions that reduce net outward current by another mechanism (14, 21, 24, 35, 36) . Consistent with this principle is our finding that reduction of endogenous (physiological) late I Na , which is a small inward current in the absence of disease (i.e., the situation in the present study), reduced arrhythmic activity in the presence of inhibitors of I to , I Kr , and I K1 . These results suggest that endogenous late I Na can be potentially proarrhythmic in the presence of other factors that reduce repolarization reserve in the ventricular myocardium.
In conclusion, inhibition of late I Na reversed the APD prolongation and arrhythmogenesis caused by inhibitors of multiple K ϩ channels. Physiological, endogenous late I Na therefore appears to play an important role in controlling repolarization in normal rabbit hearts, and it may be an important modulator of arrhythmogenicity in the heart with reduced repolarization reserve. This finding may explain the observations that late I Na inhibitors (e.g., lidocaine, mexiletine, and ranolazine) were found to be anti-arrhythmic in clinical and experimental long QT syndromes (2, 18, 24 -26, 32 ).
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